Skip to content

Based on ERAS concept to evaluate the anesthetic application of ultrasound-guided lumbosacral plexus block in critically ill elderly patients undergoing hip surgery

Based on ERAS concept to evaluate the anesthetic application of ultrasound-guided lumbosacral plexus block in critically ill elderly patients undergoing hip surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044162
Enrollment
Unknown
Registered
2021-03-12
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip surgery

Interventions

Group N (nerve block group):0.5% ropivacaine 35ml for lumbosacral plexus block combined with sedation anesthesia
Group E ( epidural and spianl anesthesia group):0.5% ropivacaine 2ml was injected into the subarachnoid space under combined spinal-epidural anesthesia.
Group G (general anesthesia group):General anesthesia with propofol, sufentanil, vecuronium and sevoflurane

Sponsors

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Unilateral osteonecrosis of the femoral head and chronic hip pain were associated with joint dysfunction, and conservative treatment was ineffective, with indications for hip arthroplasty. (2) Unilateral fractures of femoral neck and trochanter, which are to be treated with internal fixation or joint replacement. (3) Over 60 years of age. (4) ASA II or above according to the American Association of Anesthesiologists before operation. (5) Those who agreed before operation and signed the informed consent form. (6) All the operations were performed by doctors with senior seniority and professional title or above.

Exclusion criteria

Exclusion criteria: (1) Those who have a history of dependence on or allergy to narcotic drugs or analgesics. (2) Patients with neuropsychiatric diseases in the past. (3) Peripheral neuropathy. (4) Blocking infection around the site. (5) Morbid obesity (body mass index BMI > 40kg/m2). (6) Those who are unable to understand and complete the pain visual simulation scale. (7) Those who can not cooperate with functional exercise after operation.

Design outcomes

Primary

MeasureTime frame
Perioperative hemodynamic changes, including blood pressure (BP), heart rate (HR) and pulse oxygen saturation (SpO2);Postoperative pain and analgesic effect;Stress-immune response, including fasting blood glucose, c-reactive protein, white blood cell count, serum cortisol, IFN- ?, IL-10;

Secondary

MeasureTime frame
Total amount of anesthetic used during operation, including sevoflurane, propofol and sufentanil;Adverse reactions, Including postoperative hypotension, bradycardia, dyspnea, nausea and vomiting, sore throat, low back pain, headache, urine retention, puncture point pain, subcutaneous hematoma, infection or not, motor and sensory disorders in the nerve control area;Postoperative recovery;Long-term effect;

Countries

China

Contacts

Public ContactChengyi Cai

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

cycai97@163.com+86 13710505045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026